Wang Wei, Meng Tao, Chen Ying, Xu Ye-Chuan, Zhao Yi-Jun, Zhang Yan, Yang Ming-Ya, Zhang Zhi-Hua, Huang Fan, Zhao Hong-Chuan, Geng Xiao-Ping, Zhu Li-Xin
Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Department of Statistics, Anhui Medical University, Hefei, China.
Hepatobiliary Surg Nutr. 2022 Dec;11(6):808-821. doi: 10.21037/hbsn-21-45.
This study aims to find out the possible optimal therapy and assess the prognosis properly for patient with spontaneous rupture of hepatocellular carcinoma (HCC).
Propensity score matching (PSM) analysis was used to study the data from 325 patients with ruptured HCC (RHCC) and 2,291 patients with non-RHCC.
The incidence and hospital mortality of RHCC were 5.1% and 0.8% respectively, with a median overall survival (OS) time of 17 months. There was no difference between ruptured and non-RHCC patients undergoing conservation treatment in terms of OS. Trans-arterial embolization (TAE) was carried out in 69 (21.2%) cases with RHCC, with a median OS of 7 months, which was no difference from that of non-RHCC (pre- and post-PSM). One hundred and sixty-nine (52.0%) RHCC cases underwent one-stage hepatectomy, with a median OS and disease-free survival (DFS) of 30 and 6 months respectively, which were shorter than that of non-RHCC (post-PSM). TAE plus two-stage hepatectomy was performed in 30 RHCC cases, with a median OS and DFS of 28 and 10 months respectively; these outcomes were better than that from RHCC patients undergoing TAE alone or one-stage hepatectomy (post-PSM), which were no difference from that of non-RHCC patients undergoing hepatectomy. The risk of death for RHCC patient undergoing one-stage hepatectomy is 1.545 times higher than that of one undergoing TAE + two-stage hepatectomy.
TAE plus two-stage hepatectomy might be the optimal treatment for RHCC patient. Under the premise of the same pathological properties, there is no difference in prognosis between ruptured and non-RHCC patients if the therapy is appropriate.
本研究旨在探寻肝细胞癌(HCC)自发性破裂患者可能的最佳治疗方法并正确评估其预后。
采用倾向评分匹配(PSM)分析研究325例破裂性HCC(RHCC)患者和2291例非RHCC患者的数据。
RHCC的发病率和医院死亡率分别为5.1%和0.8%,中位总生存期(OS)为17个月。接受保守治疗的破裂和非RHCC患者在OS方面无差异。69例(21.2%)RHCC患者接受了经动脉栓塞(TAE),中位OS为7个月,与非RHCC患者(PSM前后)无差异。169例(52.0%)RHCC患者接受了一期肝切除术,中位OS和无病生存期(DFS)分别为30个月和6个月,短于非RHCC患者(PSM后)。30例RHCC患者接受了TAE加二期肝切除术,中位OS和DFS分别为28个月和10个月;这些结果优于单独接受TAE或一期肝切除术的RHCC患者(PSM后),与接受肝切除术的非RHCC患者无差异。接受一期肝切除术的RHCC患者的死亡风险比接受TAE +二期肝切除术的患者高1.545倍。
TAE加二期肝切除术可能是RHCC患者的最佳治疗方法。在病理性质相同的前提下,如果治疗得当,破裂和非RHCC患者的预后无差异。